Story · Longevity & Aging
MetaVia’s DA-1726 shows weight and liver fat reductions
2 outlets · first reported by Longevity.Technology 1d ago · latest 1h ago · 38 hours of coverage · 2 countries
Coverage, in order
-
1d agoMetaVia’s DA-1726 shows weight and liver fat reductions
MetaVia announced that an abstract on DA-1726, a dual oxyntomodulin analogue targeting GLP-1 and glucagon receptors, has been accepted for a poster presentation at ObesityWeek 2026 in Washington, DC. The poster, titled “DA-1726 Demonstrates Comparable Weight Loss and Distinct Metabolic Profile…
-
1h agoMetaVia’s DA-1726 lowers uric acid after earlier cuts in liver fat and weight
MetaVia, a U.S. affiliate of Dong-A ST, said Thursday (local time) that its experimental drug DA-1726 significantly lowered blood uric acid levels in an early-stage trial that had previously shown reductions in body weight and liver fat.An additional interim analysis of Part 3B of the phase 1 trial
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.